更新于：2024-05-01

Breast Cyst

乳腺囊肿

更新于：2024-05-01

基本信息

别名

BREAST CYST、Breast Cyst、Breast Cysts

+ [29]

简介

A fluid-filled closed cavity or sac that is lined by an EPITHELIUM and found in the BREAST. It may appear as a single large cyst in one breast, multifocal, or bilateral in FIBROCYSTIC BREAST DISEASE.

关联

项与乳腺囊肿相关的药物

Rujietai Capsule

乳结泰胶囊

靶点-

作用机制-

在研机构

衡水以岭药业有限公司

原研机构

衡水以岭药业有限公司

在研适应症

乳腺囊肿

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2018-07-23

项与乳腺囊肿相关的临床试验

NCT03771833 / CompletedN/A

Comparison of M5 and M6 Versions of the MARIA Imaging System on Patients Attending Symptomatic Breast Clinic in Cheltenham, United Kingdom (UK), Including a Sub-study to Research the Dielectric Constant of Aspirated Cyst Fluid

The MARIA breast imaging system is a Conformité Européenne (CE)-marked radio-frequency (RF) medical imaging device. The system employs an electromagnetic imaging technique that exploits the dielectric contrast between normal and cancerous tissues. The performance and imaging characteristic differences between the M5 and M6 versions of MARIA are not yet well demonstrated in the clinical environment, particularly with regards to cysts. The evaluation of some aspects of this potentially important new technology will occur in this comparative technical study. Further, the dielectric constant of cyst fluid is currently not well understood and obtaining readings from aspirated cyst fluid in applicable patients will be attempted.

开始日期2019-02-19

申办/合作机构

Micrima Ltd.

NCT03475992 / CompletedN/A

Pilot Clinical Evaluation of a Microwave Imaging System for Early Breast Cancer Detection

The trialed investigational medical imaging device is a low-power microwave breast imaging system for cancer screening purposes. It is an active device which uses non-ionizing radiation.
Microwave imaging is an emerging imaging modality for the early detection of the breast cancer. The physical basis of microwave imaging is the dielectric contrast between healthy and cancerous breast tissues at microwave frequencies. Microwave imaging can potentially be used for monitoring neoadjuvant chemotherapy treatment, breast health monitoring, and for routine screening and diagnosis of the breast cancer at the early-stage. The non-invasive and the non-ionizing characteristics of microwaves should allow for frequent scans of the breast using microwave imaging, unlike X-ray mammography. In addition to safety, microwave imaging does not require uncomfortable breast compression and it is potentially a lower-cost modality.
This is a first-in-human clinical test of the investigational device, which has been so far tested only with experimental phantoms modelling the human female breast.
The clinical data that will be collected in the context of this study is intended to provide early safety information for the investigational medical imaging device. In addition, this exploratory data will guide the refinement of the device hardware and the imaging algorithm design, before decision to proceed (or not) with further clinical tests.
Furthermore, this study will be used to guide sample size calculation for a subsequent study designed to evaluate efficacy should that appear warranted once this study is completed.

开始日期2018-10-10

申办/合作机构

MVG Industries SAS

IRCT201510315623N55 / Completed临床3期IIT

Effects of combined omega-3 fatty acid and vitamin E supplementation compared with the placebo on metabolic profiles, inflammatory factors and biomarkers of oxidative stress in patients with breast cystic fibrosis

开始日期2015-09-29

申办/合作机构-

100 项与乳腺囊肿相关的临床结果

登录后查看更多信息

100 项与乳腺囊肿相关的转化医学

登录后查看更多信息

0 项与乳腺囊肿相关的专利（医药）

登录后查看更多信息

1,107

项与乳腺囊肿相关的文献（医药）

2024-02-15·BMC complementary medicine and therapies

The effect of Oenothera biennis (Evening primrose) oil on inflammatory diseases: a systematic review of clinical trials.

Review

作者: Melika Sharifi ; Nasim Nourani ; Sarvin Sanaie ; Sanaz Hamedeyazdan

BACKGROUND:

Evening primrose oil (EPO), extracted from the seeds of Oenothera biennis, has gained attention for its therapeutic effects in various inflammatory conditions.

METHOD:

We performed a systematic search in multiple databases and defined the inclusion criteria based on the following PICOs: P: Patients with a form of inflammatory condition, I: EPO, C: Placebo or other therapeutic interventions, O: changes in inflammatory markers or patients' symptoms; S: randomized controlled trials. The quality of the RCTs was evaluated using Cochrane's RoB tool.

RESULTS:

Several conditions were investigated in the literature. In rheumatoid arthritis, mixed results were observed, with some studies reporting significant improvements in symptoms while others found no significant impact. EPO showed some results in diabetes mellitus, atopic eczema, menopausal hot flashes, and mastalgia. However, it did not demonstrate effectiveness in chronic hand dermatitis, tardive dyskinesia, psoriatic arthritis, cystic fibrosis, hepatitis B, premenstrual syndrome, contact lens-associated dry eyes, acne vulgaris, breast cyst, pre-eclampsia, psoriasis, or primary Sjogren's syndrome. Some results were reported from multiple sclerosis after EPO consumption. Studies in healthy volunteers indicated no significant effect of EPO on epidermal atrophy, nevertheless, positive effects on the skin regarding hydration and barrier function were achieved.

CONCLUSION:

Some evidence regarding the potential benefits of EPO in inflammatory disorders were reported however caution is due to the limitations of the current survey. Overall, contemporary literature is highly heterogeneous and fails to provide strong recommendations regarding the efficacy of EPO on inflammatory disorders. Further high-quality studies are necessitated to draw more definite conclusions and establish O. biennis oil effectiveness as an assuring treatment option in alleviating inflammatory conditions.

2024-01-31·The American surgeon

Triple-Negative or Close-to-Triple-Negative Breast Cancer Presenting as a Thick-Walled Cystic Lesion.

Article

作者: Li Gan ; Junyuan Xie ; Kaiqiang Li ; Zimeng Xu ; Xinxing Wang ; Xinhong Pei ; Bingjian Xue

Clinical and pathologic characteristics of the invasive ductal carcinoma (IDC) presenting as a thick-walled breast cyst are little known. Three female patients were included in this report. A palpable, nontender breast lump was found in all cases. While mammography showed a hyperdense mass, ultrasonography demonstrated a thick-walled cystic mass. Magnetic resonance imaging clearly showed the cystic breast lesions with ring-like or irregular rim enhancement. A grade III IDC was confirmed in all cases. All IDCs but one were estrogen receptor negative, progesterone receptor negative, and human epidermal growth factor receptor 2 negative, with merely weak progesterone receptor positivity (5%) in one case. All cases underwent surgical management first and postoperative chemotherapy. Breast malignancy presenting as a thick-walled cystic mass could be a highly aggressive IDC, even triple-negative breast cancer. It is imperative for breast cancer-related practitioners to identify the potentially malignant cystic lesions timely and adopt appropriate management.

2024-01-16·The Kurume medical journal

The Use of Pneumocystography for Navigation of Stereotaxic Core-needle Biopsy in Complex Breast Cysts: Case Report.

Article

作者: G A Belonenko ; A A Aksyonov ; N A Sukhina ; E G Aksyonova

Complex breast cysts (CBC) are characterized by a high (up to 31.0%) oncological potential and the need for a biopsy. In some clinical situations, navigating a biopsy using mammography (MG), ultrasound (US), endoscopy, and magnetic resonance imaging (MRI) may be difficult. The first case of stereotaxic core-needle biopsy (sCNB) under pneumocystography (PCG) guide is presented.

项与乳腺囊肿相关的新闻（医药）

2023-07-31

·Medical Design and Outsourcing

MIT researchers build wearable ultrasound scanner for earlier breast cancer detection

A wearable ultrasound scanner developed by researchers at MIT could improve the survival rate of breast cancer patients. The researchers 3D-printed a flexible patch that can attach to a bra using magnets. The patch has six openings where a miniaturized ultrasound scanner can contact the skin and image the wearer’s breast tissue from different angles. The goal is to detect breast cancer earlier with more frequent screening for patients at high risk. “We changed the form factor of the ultrasound technology so that it can be used in your home,” MIT Media Lab Associate Professor Canan Dagdeviren, who designed the miniaturized scanner, said in a news release. “It’s portable and easy to use, and provides real-time, user-friendly monitoring of breast tissue.” MIT graduate student Wenya Du, Research scientist Lin Zhang, Emma Suh and Xi’an Technological University professor Dabin Lin are the lead authors of the paper, published in Science Advances. The team said their device image resolution is comparable to those generated by probes in medical imaging centers, and can image tissue at a depth of up to 8 cm. Right now, their reusable system connects to an ultrasound machine like you’d see at an imaging center, but the researchers say they’re working on a smartphone-sized version for use at home or anywhere else, anytime. “Breast cancer is the most common cancer among women, and it is treatable when detected early,” said Massachusetts General Hospital breast cancer surgeon Dr. Tolga Ozmen, another author of the study. “One of the main obstacles in imaging and early detection is the commute that the women have to make to an imaging center. This conformable ultrasound patch is a highly promising technology as it eliminates the need for women to travel to an imaging center.” MIT School of Engineering Dean Anantha Chandrakasan cited advances in materials, low-power circuits, AI algorithms and biomedical systems for the device’s development. “This work will significantly advance ultrasound research and medical device designs.” Previously: MIT engineers develop wearable, stamp-sized ultrasound stickers for continuous imaging A personal mission Dagdeviren drafted a rough schematic of the device at the bedside of her late aunt, who died six months after being diagnosed with late-stage breast cancer at 49 despite regular screenings. MIT said 20% to 30% of all breast cancer cases are interval cancers, or tumors that develop in between regularly scheduled mammograms. “My goal is to target the people who are most likely to develop interval cancer,” Dagdeviren said. “With more frequent screening, our goal to increase the survival rate to up to 98 percent.” Breast cancer patients diagnosed in the earliest stages are nearly certain to survive, but the survival rate is only around 25% for tumors spotted in later stages. The first patient — and what’s next The researchers worked with MIT’s Center for Clinical and Translational Research to test their wearable ultrasound scanner on a single patient. In that woman, a 71-year-old with a history of breast cysts, the device detected cysts as small as 0.3 cm diameter, the same size as early-stage tumors. “Access to quality and affordable health care is essential for early detection and diagnosis,” said Catherine Ricciardi, CCTR nurse director and an author of the study. “As a nurse I have witnessed the negative outcomes of a delayed diagnosis. This technology holds the promise of breaking down the many barriers for early breast cancer detection by providing a more reliable, comfortable, and less intimidating diagnostic.” The researchers hope to use artificial intelligence to analyze how images of a patient’s breast tissue change over time. That could help more accurately diagnose tumors than images taken years apart. The researchers also plan to look into adapting their werable ultrasound technology for other parts of the body. Related: AI breakthroughs in medtech: 7 ways to enhance healthcare

2022-10-25

·动脉网

13分钟让乳腺结节缩小0.05mm！十倍好医疗跑通“慢病健康管理”新模式

利用生物电细胞共振，能否解决毛细血管水肿造成的乳房胀痛、乳腺增生、前列腺增生、假性近视等未达到手术级别病痛问题？生物技术公司Novocure（纳斯达克证券交易所代码：NVCR）做过类似的探索。其自主研发的电场疗法疾病控制率高达91%，且相关电场治疗系统NovoTTF-100L已获FDA批准，用于治疗脑膜间皮瘤。该治疗方式的原理即通过电场的特定频率，精准破坏各类处于快速有丝分裂的癌细胞，从而阻止癌细胞增殖生长。不过，针对电场疗法，相关研究又得出新的结论。2021年10月13日，哈佛大学医学院马秋富教授团队与复旦大学王彦青教授、中国中医科学院针灸研究所景向红教授团队合作，在国际顶尖学术期刊《Nature》发表论文表示，诱发迷走传出神经的放电，可抑制LPS诱导的促炎细胞因子释放，进而显著提高动物的存活率。哈佛大学医学院马秋富教授团队发表在Neuron的研究论文这一部分研究结果，几乎模拟了低强度电针刺激后肢穴位ST36的抗炎效果。即通过生物电刺激的方式，消除毛细血管的水肿，从而达到消除相关炎症的效果。可喜的是，近年来通过生物电细胞共振这一纯物理、非药物治疗方式，已广泛应用于早期疾病诊断、生物组织液检测和生理状态评估等领域。面对中国3.401亿有乳腺增生、乳腺结节、多发性乳腺囊肿患者，以及4亿有前列腺肥大、前列腺增生男性。十倍好医疗科技（广州）有限公司（以下简称“十倍好医疗”）以此原理为基础，将自研AI生物电共振芯片和柔性传感电路置入内衣中，以更小、更便携，且更方便患者使用的形式，解决乳房胀痛、乳腺增生、前列腺增生、假性近视等未达到手术级别病痛问题。以低成本，扩大使用人群范围，把更多人“阻拦”在做手术的路上。十倍好医疗创始人黄锦华告诉动脉网：“中国每年新增30万乳腺癌用户，但目前医院只有针对乳腺增生达到4a级以上患者的‘乳腺微创+乳腺切除’手术解决方案。中国人口协会发布的《中国乳腺疾病调查报告》显示，无症状乳腺疾病患者高达52.4%，仅患乳腺增生的妇女就高达49.7%。一般情况下，乳腺增生无需手术治疗，其癌变率大约为0.1%。换言之，即中国目前有3.4亿乳腺增生、结节患者，但大部分处在1级到4级之间，且并不需要做手术。我们要做的就是为这部分患者提供未病先防，既病防变的解决方案。”建立健康监测+理疗设备+配套耗材闭环，自研AI生物电芯片可穿戴内衣或纳入医保事实上，电场疗法早在2011年就已获FDA批准用于治疗复发性胶质母细胞瘤。但其在健康管理场景的应用，却相对稀缺。黄锦华注意到了这一技术的价值，自研AI生物电细胞共振芯片，切入科技康养赛道，同时建立元気之羽AI生物电内衣、AI生物电芯片儿童降度眼镜框、慢病康复综合理疗舱等多条产品线。团队将产品落地过程拆解为两步。第一步，研发能产生共振频率的AI生物电芯片；第二步，将载有远红外线8.7-9.34共振频率的生物电芯片，做成柔性电路，应用到服装或智能穿戴、医疗保健设备中，靶向解决组织间隙毛细血管水肿造成的各种慢性疾病。一般情况下，人体心脏细胞正负电压差为110毫伏，亚健康细胞正负电压差为80-90毫伏，癌症细胞的正负电压差为30-40毫伏。正负电压差越低，就证明细胞的活性越低。要想疏通胸涨、胸痛、结节、囊肿等慢性疾病问题，就要恢复细胞生物电电压差，以及其细胞活性。十倍好医疗历时6年，自主研发AI生物电细胞共振芯片。其主要构成为柔性电路石墨烯、碳纳米管与基于AI的磁场感应式NPU。该生物电共振芯片的共振波的波长范围为8.7-9.34微米。企业将该AI生物电细胞共振芯片做成柔性电路芯片，以柔软灵活的形式，将生物电共振芯片，用超声波贴合到文胸的罩杯、侧比中。该芯片可释放8.7-9.34微米的生物电共振波，通过与人体细胞每日长达8小时的同频共振，可为淤堵的乳腺细胞补充生物电，恢复其膜电位差，瞬间激活细胞活性，打通乳腺的微循环，从而达到疏通乳腺的效果。不仅如此，该发明还将载有远红外共振波的芯片设于罩杯贴近皮肤一侧。当人体穿戴内衣时，远红外芯片发射共振波渗入人体内后，引起人体细胞的原子和分子共振。当分子之间摩擦形成热反应，便可促使皮下深层温度上升，以及微血管扩张，进一步加速血液循环，疏通淤堵的乳腺，达到调整人体生物电磁场和预防女性乳腺增生、乳腺结节、多发性乳腺囊肿等乳腺疾病的作用。目前该芯片对细胞理疗效果，已获美国SCI论文（Far-infrared ray radiation promotes neurite outgrowth of neuron-like PC12 cells through AKT1 signaling）验证。据江苏人民医院附属徐州肿瘤医院B超现场测试结果显示，在B超影像的监控下，针对不同乳腺问题的用户使用100核芯片，其中之一于5分钟内实现乳腺纤维瘤变细，另一实现10分钟让乳腺囊肿缩小0.3厘米，另一实现13分钟内，乳腺结节从0.61厘米变为0.56厘米。在内蒙古包钢医院、内蒙古包钢医院中西医院分院、内蒙古医科大学第三临床医学院进行的生物电共振芯片临床对照实验中，结果显示该产品治疗前列腺增生的有效率为75.68%。两项实验，进一步验证了该生物电共振芯片的有效性。芯片对前列腺临床有效理疗率图片来源：十倍好医疗2021年，中国康复医学会则发布“关于开展《生物电共振芯片对乳腺结节治疗效果观察》的函”，对生物电共振芯片在乳腺结节治疗中的应用，给出了肯定意见。并表示生物电共振芯片针对乳腺结节治疗有明确效果，可以缩小或消除结节，减轻病人的心理负担，保障乳腺健康。据悉，生物电芯片是十倍好医疗研发多年的技术成果。目前已迭代到第7代芯片，并获得十多项国家发明专利与PET国际专利授权。同时，AI生物电芯片可耐近1000次洗衣机的洗涤，并能承受数百次重复弯曲，即使弯曲到小于3.5 mm的半径时也能保持其性能。从而可以应用到贴身衣物中，譬如文胸、内裤中。黄锦华表示：“目前，十倍好医疗自主研发的慢病康复综合理疗舱，以及AI生物电芯片儿童降度眼镜框已递交审批程序，预计明年取得二类医疗器械注册证。元気之羽AI生物电内衣正在准备申请一类医疗器械注册证，同时该系列产品获得乳腺专家看好，称未来或纳入医保。”打通三甲医院做品牌高度，建立元気之羽医养科技生活馆做用户宽度筑稳了地基，十倍好医疗将目光投向7.4亿国人的慢病问题。据中商产业研究院发布的《2020年中国中医药行业市场前景及投资机会研究报告》显示，到2020年中国健康产业产值将达到8万亿，到2030年达到16万亿元，成为国民经济支柱产业。十倍好要做的就是以AI生物电芯片为核心，依托“健康监测+理疗设备+配套耗材”的模式，以用户口碑效果为裂变扩张模式，借力线下实体店加强用户体验，在监测治疗改善调理7.4亿国人慢病问题的同时，实现规模化增长。十倍好医疗商业模式据了解，十倍好医疗建立了元気之羽AI芯片内衣这一硬科技新消费品牌，以医疗科技嫁接消费品。此外，公司还以AI芯片为基础，开发出能进入三甲医院的慢病理疗设备，以及AI生物电轻医美、AI生物电儿童降度镜等储备产品。计划以科技养生品牌连锁的形式，覆盖更广泛人群，最终成为规模最大的健康内衣品牌，店铺最多的科技康养渠道。目前，这些储备产品，均已实现量产。内衣等相关产品已投入四川、广东、浙江、湖南、江西、山西、山东、福建等地。截止6月30日，AI理疗舱+AI智能文胸——DAU（Daily Active User，日活跃用户数量）约为21200人，MAU（Monthly Active User，月活跃用户数量）约为56000人。同时线下门店年复购频次已从过去3-5次，提升到21次以上，客单值提升了12倍。不仅如此，据企业提供信息显示，企业自主研发的以600核AI生物电芯片为核心的理疗舱，在多家医院试点后，对患者的肩周炎、筋膜炎、失眠、降低血脂、降低血压、脂肪瘤、乳腺囊肿等未达手术和药物级别的疾病，效果良好。目前十倍好医疗以此为契机，与国药集团、中国健康养老科技集团等企业持续探讨深度合作模式。事实上，今年4月，在国务院办公厅印发的《“十四五”国民健康规划》中便提及，围绕人口老龄化趋势以及健康中国发展战略，将从预防、诊断、治疗三个层次，从“治病为中心“，转为以”防病为中心”，从“治病模式”到“防病模式”的转变。而十倍好医疗在做的，正是以AI生物电细胞共振芯片为地基，持续推出医养结合的创新健康解决方案，以最终实现从“治病模式”到“防病模式”的转变。如果您想对接动脉网所报道的企业，请扫描小程序码进入VB100人脉圈查看。近期推荐声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。动脉网，未来医疗服务平台